Akums Drugs and Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.

Emphasis Of MatterExceptional ItemResults View source PDF Explain this filing

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹482.40

prior close

₹485.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.2%-0.8% vs market

Pharmaceuticals peers, median of 148sector+0.3%-1.0% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

+2.6

15m

+2.4

30m

+1.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6+0.2-0.8+0.3-1.0

Next day

-0.4+0.2-0.6+0.3-0.7

+1.3+0.9+0.4+0.6+0.6

-2.2+0.1-2.2-0.3-1.8

-1.6+1.6-3.2+0.5-2.2

-0.6+2.8-3.4+0.6-1.1

-0.2+3.0-3.3+0.8-1.0

15d

-1.1+2.8-3.9+0.1-1.3

-4.6+3.1-7.7+1.5-6.1

-3.6+1.4-5.1-1.5-2.1

-9.2+1.4-10.6-4.2-5.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Akums Drugs and Pharmaceuticals Limited announced its unaudited Q1 FY26 results on August 8, 2025. Consolidated revenue from operations stood at ₹10,240.32 million, almost flat versus ₹10,191.13 million in Q1 FY25 (about 0.5% growth). Consolidated profit after tax rose to ₹646.85 million from ₹612.08 million, while standalone PAT grew to ₹448.67 million from ₹418.75 million. Consolidated EPS was ₹4.15 and standalone EPS was ₹2.93. The CDMO segment continued to dominate, contributing roughly 80% of revenue, while the API and Trade Generics segments remained in losses. The auditor flagged an emphasis-of-matter note relating to the Income Tax Department's search and seizure operation conducted between January 15-21, 2025, for which no order or demand has been received yet. The Board also re-appointed the internal auditor, reconstituted key committees, and designated two senior management personnel.

Likely market impact

A largely flat-to-modestly-positive quarter for shareholders, with single-digit PAT growth and stable revenue. The pending Income Tax investigation remains an unresolved overhang and was specifically called out by auditors, which investors should monitor closely for any future demand or order.